Eton Pharmaceuticals (NASDAQ:ETON) Shares Gap Up After Better-Than-Expected Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON)’s stock price gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $47.15, but opened at $58.59. Eton Pharmaceuticals shares last traded at $52.2910, with a volume of 215,792 shares changing hands.

The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $57.93 million during the quarter, compared to analysts’ expectations of $41.98 million.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record Q3 product sales reached $57.9 million, up 158% year over year. Eton said it exceeded its $200 million annualized revenue run-rate goal five quarters ahead of schedule. Eton Q3 2026 financial results
• Positive Sentiment: The company raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to more than 40%, from more than 35%. Q3 adjusted EBITDA was $28.5 million, or 49% of revenue. Eton Q3 2026 financial results
• Positive Sentiment: Q3 fully diluted GAAP EPS was $1.06, versus the Zacks consensus estimate of $0.34; non-GAAP fully diluted EPS was $0.50. Revenue also exceeded analyst expectations of about $42 million. Eton Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management highlighted growth and rare-disease pipeline progress, including preliminary ET-700 pilot-study results assessing copper absorption inhibition and gastrointestinal tolerability. The available report details do not specify the study findings. ET-700 pilot study announcement

Analyst Ratings Changes

Several equities research analysts have recently commented on ETON shares. Craig Hallum restated a “buy” rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. B. Riley Financial reiterated a “buy” rating and set a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, HC Wainwright upped their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $74.00.

Insider Transactions at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the sale, the director owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Krempa sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the transaction, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 79,166 shares of company stock valued at $4,809,672. Corporate insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $1,531,000. Bank of New York Mellon Corp purchased a new position in shares of Eton Pharmaceuticals in the second quarter worth $4,281,000. Squarepoint Ops LLC bought a new position in shares of Eton Pharmaceuticals during the second quarter worth $2,156,000. Jefferies Financial Group Inc. bought a new position in shares of Eton Pharmaceuticals during the second quarter worth $1,232,000. Finally, Bank of Nova Scotia purchased a new position in Eton Pharmaceuticals during the second quarter valued at $623,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Up 13.0%

The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $1.52 billion, a PE ratio of 140.19 and a beta of 0.89. The company’s 50 day moving average is $54.92 and its two-hundred day moving average is $36.26.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.